Media / News


Welcome to Amphastar Pharmaceuticals’ Media/News where our Press Releases give you insight into what is happening now at Amphastar and other industry NEWS about our fast-growing, innovative company.


We invite you to learn more about us at news and view postings of upcoming events that we believe are of interest to our customers and investors.

CEO                                        Jack Zhang, Ph.D.


President                               Jason Shandell, MBA, JD


Corporate Headquarters      11570 6th Street, Rancho Cucamonga, CA., USA


Founded                                1996


Business                               Generics, Specialty Pharmaceuticals, APIs


Workforce                             1,300


2013 Revenue (USD)            $230 mm


Stock Exchange Nasdaq:    AMPH


Products                                15


Facilities                                Over 1.1 million sq. ft. with 5 manufacturing sites

                                               Amphastar Pharmaceuticals, Inc., Rancho Cucamonga, CA

                                               International Medication Sys., Ltd., So. El Monte, CA

                                               Armstrong Pharmaceuticals, Inc., Canton, MA

                                               Amphastar Nanjing, Nanjing, China

                                               Amphastar France Pharmaceuticals, France



Amphastar is a specialty pharmaceutical company that is engaged in developing, manufacturing, marketing, and selling generic and proprietary injectable and inhalation pharmaceutical products.


Most of the products we currently sell are used in hospital or urgent care clinical settings and are primarily sold through group purchasing organizations and drug wholesalers.


We are also currently engaged in the development of our own branded product candidates that build on our scientific expertise in developing generic products.


Utilizing our highly experienced professionals and proven ability to develop and manufacture technically difficult products often with significant barriers to the market and produce our own API that is not readily available, we currently have 16 drug products in the market and a robust pipeline that provides a strong probability of sustained growth.

Company Information


For Media Information





Copyright © 2018 Amphastar Pharmaceuticals, Inc.

Privacy      Terms & Conditions

This site is intended for residents of the United States